



Introducing



FLYRCADO™

flurpiridaz F 18 injection

Meet the F 18 radiotracer that’s changing what’s possible in cardiac PET

Flyrcado is a diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Harness the full potential of PET MPI with Flyrcado

<p>Convenient unit dose delivery</p> <p>Order as needed with <u>no</u> patient-volume minimums - <u>no</u> generator required¹</p>	<p>Unmatched flexibility</p> <p>110-minute half-life allows exercise or pharmacologic stress; reimage if needed in event of technical difficulties²</p>	<p>Exceptional image quality</p> <p>High extraction fraction and short positron range yield excellent resolution¹</p>	<p>Greater diagnostic certainty</p> <p>Superior CAD detection vs SPECT in overall population and difficult-to-image patients^{2,3}</p>	<p>GE HealthCare expertise</p> <p>Comprehensive support from our specialized PET experts</p>
--	---	---	---	---

Society guidelines recommend PET MPI for a growing group of difficult-to-image patients, including;⁴



Obese



Dense breasts or breast implants



Multivessel CAD

References

- Maddahi, J., & Packard, R. R. (2014). Cardiac PET perfusion tracers: current status and future directions. *Seminars in Nuclear Medicine*, 44(5), 333-343. <https://doi.org/10.1053/j.semnuclmed.2014.06.011>.
- Flyrcado (flurpiridaz F 18) injection. Full Prescribing Information. Marlborough, MA: GE HealthCare.
- Maddahi, J., et al. (2023). Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. *Journal of the American College of Cardiology*, 82, 1598-1610. <https://doi.org/10.1016/j.jacc.2023.08.016>.
- Schindler TH, et al. *J Nuc/ Med*. 2020;61(8):1221-1265


Please see Important Safety Information beginning on page 6 and full Prescribing Information [here](#).

Taking quality and clarity to the next level


High spatial resolution informs precise diagnosis and prognostic value¹

Series of Flyrcado images²

PHARM STRESS



REST




High uptake in the myocardium^{3,4}

Excellent image contrast³

Reliable detection of extent and severity of ischemia³

Better ability to detect mild perfusion defects^{3*}

*Versus single-photon emission computed tomography (SPECT) MPI imaging



References

1. Patel, Krishna K et al. "The Potential of F-18 Flurpiridaz PET/CT Myocardial Perfusion Imaging for Precision Imaging." Current cardiology reports vol. 24,8 (2022): 987-994. doi:10.1007/s11886-022-01713-5.
2. Maddahi, J., et al. (2023). Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 82, 1598-1610. <https://doi.org/10.1016/j.jacc.2023.08.016>.
3. Maddahi, J., & Packard, R. R. (2014). Cardiac PET perfusion tracers: current status and future directions. Seminars in Nuclear Medicine, 44(5), 333-343. <https://doi.org/10.1053/j.semnuclmed.2014.06.011>.
4. PI: Flyrcado (flurpiridaz F 18) injection. Full Prescribing Information. Marlborough, MA: GE HealthCare.

Please see Important Safety Information beginning on page 6 and full Prescribing Information [here](#).




Flyrcado's half-life offers unrivaled flexibility to support your workflow and patient needs¹

Imaging protocol at a glance


Pharmacological stress

- When imaging at rest and during pharmacologic stress, data acquisition should begin 10 seconds before tracer injection
- Recommended 30 minutes duration between injections, **whether rest or stress**
- No need to stop and re-dose patient in case of motion



Exercise stress (may be done in a separate room)

- To allow time to recover from exercise and minimize motion artifact, acquisition should start 15-25 minutes post exercise
- Recommended 60 minutes duration between injections, **whether rest or stress**
- No need to stop and re-dose patient in case of motion



Reference

1. PI: Flyrcado (flurpiridaz F 18) injection. Full Prescribing Information. Marlborough, MA: GE HealthCare.

Flyrcado offers superior sensitivity and diagnostic accuracy compared to SPECT in populations with suspected CAD




Flyrcado PET demonstrated **superior sensitivity and noninferior specificity** compared to SPECT in a phase 3 multicenter clinical trial (AURORA; N=578).¹

Flyrcado demonstrated **superior image quality** compared to SPECT (96.2% vs. 78.2% excellent or good quality images; P<0.0001).¹

Sensitivity was also **significantly higher** compared to SPECT in women-only subgroups and patients with BMI >30kg/m².¹

Flyrcado was associated with significantly higher diagnostic certainty (84.9%) versus SPECT (52.1%; P<0.0001).¹

Comparative diagnostic accuracy of Flyrcado vs. SPECT¹



† Specificity P-values represent noninferiority analyses. **Abbreviations:** BMI=body mass index; CAD=coronary artery disease; PET=positron emission tomography; SPECT=single-photon emission computed tomography; US=United States.

Reference


1. Maddahi, J., et al. (2023). Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 82, 1598-1610. <https://doi.org/10.1016/j.jacc.2023.08.016>.

Please see Important Safety Information beginning on page 6 and full Prescribing Information [here](#).



Now FDA approved and available in select US markets beginning early 2025

Flyrcado is generally available within a ~200-mile radius of the location of each contracted manufacturing organization (CMO)*



*The CMO network for Flyrcado is continually expanding. Speak to your rep to find when Flyrcado will be available in your region.

Contact us

As the industry's singular provider of both advanced imaging technologies and proprietary radiotracers, our team of multidisciplinary GE HealthCare experts is here to support all of your needs.

Reach out to your regional GE HealthCare Cardiac PET Sales Manager to get started.

Be Flyrcado Forward.

Scan the QR code to sign up now for continued guidance and resources to expand access to cardiac PET for your patients.



IMPORTANT SAFETY INFORMATION

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

- Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.
- Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

- Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence $\geq 2\%$) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

Use in Specific Populations

Pregnancy: There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.

Lactation: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.

Pediatric Use: Safety and effectiveness of FLYRCADO in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch.

Flyrcado Support Line: 800 729 0701

Medical Affairs: 800 654 0118
(option 2, then option 3) or
medical.affairs@gehealthcare.com

Customer Service: 800 292 8514

gehealthcare.com

 **FLYRCADO**[™]
flurpiridaz F 18 injection



© 2025 GE HealthCare

Flyrcado is a trademark of GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

April 2025 JB11163US